###begin article-title 0
###xml 69 91 69 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 69 90 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Detection of atovaquone-proguanil resistance conferring mutations in Plasmodium falciparum cytochrome b gene in Luanda, Angola
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 119 141 119 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 386 405 386 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium (pfcytb)</italic>
###xml 444 452 444 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 487 494 487 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pfcytb </italic>
###xml 119 140 <span type="species:ncbi:5833">Plasmodium falciparum</span>
The fixed dose combination atovaquone-proguanil is a recently introduced antimalarial for treatment and prophylaxis of Plasmodium falciparum malaria. It is highly effective with a good tolerability profile and a convenient prophylactic regimen. Nevertheless, cases of treatment failure have already been reported, which have been associated to mutations in the cytochrome b gene of the Plasmodium (pfcytb). The presence of atovaquone-proguanil in vivo resistance conferring mutations in pfcytb gene in Luanda, Angola, was investigated, in order to make recommendations on prescribing this antimalarial as prophylaxis for travellers.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 178 185 178 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pfcytb </italic>
###xml 46 54 <span type="species:ncbi:9606">children</span>
Two hundred and forty nine blood samples from children hospitalized at Luanda Pediatric Hospital for malaria were studied. The PCR-RFLP methodology was used in order to identify pfcytb wild type codon 268 and two point mutations: T802A and A803C.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 45 52 45 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pfcytb </italic>
All samples were identified as wild type for pfcytb gene at codon 268. In the studied population, no mutations associated to atovaquone-proguanil treatment failure were found. Prevalence of the studied mutations in the region was estimated to be less than 0.77% (99% significance level).
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
Atovaquone-proguanil can be recommended for use by travellers to Luanda with expected high efficacy. This represents an improvement compared to other currently used prophylatic antimalarials in this region. However, it is imperative to continue surveillance.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 151 152 151 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 321 343 321 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 344 345 344 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 346 347 346 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 487 488 487 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 558 559 558 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 321 342 <span type="species:ncbi:5833">Plasmodium falciparum</span>
In the past decades, international travel has increased and more than 125 million international travellers visit malaria endemic countries every year [1]. This has turned the attention of scientific and public health authorities to the problem of imported and introduced malaria. The leading cause of imported malaria is Plasmodium falciparum [2-6] and antibody reaction to the parasite circumsporozoite antigen among international travellers has shown a high prevalence of inoculation [7]. Infection is especially relevant in sub-Saharan Africa travellers [7].
###end p 11
###begin p 12
###xml 205 206 205 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 207 208 207 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 209 210 209 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 355 356 355 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 357 358 357 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 359 360 359 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
Accordingly, the number of imported malaria cases has increased. There are approximately 30,000 cases of imported malaria notified per year in non-endemic countries with important morbidity and mortality [2-6,8]. Both these indices can be lowered by adequate prophylaxis. Indeed, most cases of malaria are due to non-compliance or inadequate prophylaxis [4,5,9]. It is, therefore, imperative to find a chemoprophylactic antimalarial with a good tolerability and safety profile as well as an attractive prophylactic regimen.
###end p 12
###begin p 13
###xml 89 92 89 90 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 156 170 154 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 236 250 234 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 264 271 262 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pfcytb)</italic>
###xml 380 382 378 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 383 385 381 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 413 415 411 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 522 524 520 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 525 527 523 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 648 650 646 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 739 753 737 751 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 754 756 752 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 757 759 755 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 156 169 <span type="species:ncbi:5833">P. falciparum</span>
###xml 236 249 <span type="species:ncbi:5833">P. falciparum</span>
###xml 739 752 <span type="species:ncbi:5833">P. falciparum</span>
The fixed-dose combination of 250 mg atovaquone and 100 mg proguanil per tablet (Malarone(R)) has recently been introduced for treatment and prophylaxis of P. falciparum malaria. Based on its similarity to ubiquinol, atovaquone acts on P. falciparum cytochrome b (pfcytb), affecting the parasite mitochondrial respiratory chain and collapsing the mitochondria membrane potential [10-12]. This leads to apoptosis [12]. In addition, the combination also blocks dihydroorotate dehydrogenase, inhibiting pyrimidine synthesis [11,13]. Proguanil enhances the ability of atovaquone to collapse the mitochondrial membrane by a mechanism still unexplained [14]. The combination effectively inhibits the development of the liver and blood stages of P. falciparum [15-17].
###end p 13
###begin p 14
###xml 99 101 99 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 102 104 102 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
As recently reviewed atovaquone-proguanil is highly effective as prophylaxis for up to six months [18,19] with an improved tolerability profile, a more convenient prophylactic regimen and better compliance.
###end p 14
###begin p 15
###xml 113 115 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 314 316 314 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 317 319 317 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
It is now recommended as a prophylactic alternative to mefloquine or doxycycline in chloroquine-resistant areas [20]. Nevertheless, in many countries it is considered the first line antimalarial for prophylaxis in areas of chloroquine resistance and for imported malaria treatment (including emergency treatment) [21,22].
###end p 15
###begin p 16
###xml 100 107 100 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pfcytb </italic>
###xml 174 176 174 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 177 179 177 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
There have been some reports of atovaquone-proguanil treatment failure in travellers, associated to pfcytb gene mutations, particularly at codon 268, namely T802A and A803C [23-27]. Epidemiologic surveillance of emerging resistance to this combination can be done by screening for these mutations.
###end p 16
###begin p 17
###xml 37 45 37 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 80 87 80 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pfcytb </italic>
The presence of atovaquone-proguanil in vivo resistance conferring mutations in pfcytb gene in Luanda, Angola, was investigated. This was done in order to estimate the prevalence of these mutations in this region and make recommendations on prescribing this antimalarial as prophylaxis for travellers.
###end p 17
###begin title 18
Methods
###end title 18
###begin p 19
###xml 42 50 <span type="species:ncbi:9606">children</span>
Infected blood samples were obtained from children younger than 12 years of age hospitalized at Luanda Pediatric Hospital, Angola, during the years of 2003/2004. Both the hospital and IHMT Ethics Committee approved all the applied protocols.
###end p 19
###begin p 20
###xml 133 135 133 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 417 431 417 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 509 511 509 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 600 607 600 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pfcytb </italic>
###xml 626 628 626 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 629 631 629 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 674 675 674 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 903 906 897 900 <sup xmlns:xlink="http://www.w3.org/1999/xlink">st </sup>
###xml 1002 1005 978 981 <sup xmlns:xlink="http://www.w3.org/1999/xlink">nd </sup>
###xml 1101 1104 1059 1062 <sup xmlns:xlink="http://www.w3.org/1999/xlink">td </sup>
###xml 1155 1158 1107 1110 <sup xmlns:xlink="http://www.w3.org/1999/xlink">th </sup>
###xml 1276 1278 1228 1230 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1385 1389 1336 1340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq </italic>
###xml 267 275 <span type="species:ncbi:9606">children</span>
###xml 417 430 <span type="species:ncbi:5833">P. falciparum</span>
An estimated prevalence of mutation T802A and A803C of 0.77 and 0.96%, respectively, was considered for population size calculation [27]. For an expected prevalence of 0.77%, with a significance level of 99%, the size of the studied population should be at least 213 children (StatCal, EpiInfoVersion 6, CDC, Atlanta). Samples were individually spotted on Whatman no 4 filter paper, after microscopic confirmation of P. falciparum infection. Chelex DNA extraction was done according to established protocols [28]. A modified semi-nested PCR-RFLP method was carried out to search for polymorphisms in pfcytb (T802A and A803C) [24,29]. Primer sequences are presented in Table 1. All amplifications were performed in an I-Cycler-IQ, BIO-RAD, thermocycler. The first amplification using the "OD/OR" primers was designed to produce a 716 bp fragment in the following conditions: 92degreesC (three minutes) (1st segment - 1 cycle); 92degreesC (30 seconds), 57degreesC (30 seconds), 72degreesC (one minute) (2nd segment - 9 cycles); 92degreesC (30 seconds), 52degreesC (30 seconds) 72degreesC (one minute) (3td segment - 34 cycles); 72degreesC (three minutes) (4th segment - 1 cycle). This amplicon contained all the single point polymorphisms. Reagent concentrations were: 1 mM MgCl2 (Fermentas, Lithuania), 10 muM primers (MWG-Biotech AG, Germany), 1 mM dNTPs (Fermentas, Lithuania), 120 U Taq polymerase (Fermentas, Lithuania), 500 ng DNA template from field samples. Outer PCR product was further diluted (1:50) and 1 muL of this solution was used for the second amplification.
###end p 20
###begin p 21
###xml 47 54 47 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pfcytb </italic>
Primer sequences used for the amplification of pfcytb codon 268.
###end p 21
###begin p 22
Small case indicates base changes to provide digest sites for restriction enzymes to distinguish wild type from mutations at codon 268. O: outer PCR; D: direct primer; R: reverse primer; Wt: wild type.
###end p 22
###begin p 23
###xml 274 277 268 271 <sup xmlns:xlink="http://www.w3.org/1999/xlink">st </sup>
###xml 373 376 349 352 <sup xmlns:xlink="http://www.w3.org/1999/xlink">nd </sup>
###xml 526 529 478 481 <sup xmlns:xlink="http://www.w3.org/1999/xlink">th </sup>
In the second amplification (nested or semi-nested amplification), three different pairs of primers were used, namely OD/WtR; 802D/802R; 803D/OR to distinguish between the three polymorphisms. The following conditions were used for amplication: 92degreesC (three minutes) (1st segment - 1 cycle); 92degreesC (30 seconds), 65degreesC (30 seconds), 72degreesC (one minute) (2nd segment - 9 cycles); 92degreesC (30 seconds), 60degreesC (30 seconds) 72degreesC (one minute) (3td segment - 34 cycles); 72degreesC (three minutes) (4th segment - 1 cycle). Reagent concentrations were the same as for the first amplification. The products of the second amplification were confirmed by electrophoresis in ethidium bromide-stained 3% agarose gel.
###end p 23
###begin p 24
###xml 171 172 163 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
For RFLP analysis, 4 muL of each nested product was used, with 0.1 U of each enzyme and specific buffer in a 20 muL final volume, incubated overnight at 37degreesC. Table 2 summarizes primer pairs and restriction enzymes used for the identification of each polymorphism.
###end p 24
###begin p 25
###xml 73 80 73 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pfcytb </italic>
Primer pairs and restriction enzymes used for the identification of each pfcytb codon 268 polymorphism.
###end p 25
###begin p 26
Wt: wild type; bp: base pairs; D: direct primer; R: reverse primer.
###end p 26
###begin p 27
###xml 39 53 39 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 54 61 54 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pfcytb </italic>
###xml 126 133 126 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pfmdr1 </italic>
###xml 161 167 161 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">serca </italic>
###xml 177 197 177 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium chabaudi </italic>
###xml 221 227 221 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dra-I </italic>
###xml 231 236 231 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cai-I</italic>
###xml 39 52 <span type="species:ncbi:5833">P. falciparum</span>
###xml 177 196 <span type="species:ncbi:5825">Plasmodium chabaudi</span>
The laboratory-established clone K1 of P. falciparum (pfcytb wild type) was used as amplification reaction intrinsic control. Pfmdr1 gene from the 3D7 clone and serca gene from Plasmodium chabaudi have a cutting site for Dra-I and Cai-I, respectively. They were used as restriction reaction positive controls.
###end p 27
###begin title 28
Results
###end title 28
###begin p 29
###xml 105 106 105 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
Two hundred and forty nine blood samples were collected. DNA was successfully amplified from 224. Figure 1 illustrates the result of restriction of each of the second amplification products with the corresponding enzyme.
###end p 29
###begin p 30
###xml 37 44 37 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pfcytb </italic>
###xml 0 82 0 82 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Restriction digests for detection of <italic>pfcytb </italic>codon 268 mutations on field samples. </bold>
###xml 178 187 178 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mph1103-I</italic>
###xml 421 426 421 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dra-I</italic>
###xml 656 661 656 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cai-I</italic>
Restriction digests for detection of pfcytb codon 268 mutations on field samples. A. 600 bp amplification product with the primer pair for wild type (TAT) detection, digested by Mph1103-I; lane 1 and 7 - non-digested PCR product; lane 2 - K1 wild type; lanes 3-6, 8 field isolates. MWM - 100 bp molecular weight marker. B. 146 bp amplification product with the primer pair for mutation T802A (AAT) detection, digested by Dra-I; lane 1 and 7 - non-digested PCR product; lane 2 - K1 wild type; lanes 3-6 field isolates. MWM - 100 bp molecular weight marker. C.173 bp amplification product with the primer pair for mutation A803C (TCT) detection, digested by Cai-I; lane 1 and 7 - non-digested PCR product; lane 2 - K1 wild type; lanes 3-6 field isolates. MWM - 100 bp molecular weight marker.
###end p 30
###begin p 31
###xml 79 86 79 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pfcytb </italic>
###xml 107 116 107 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mph1103-I</italic>
###xml 288 302 288 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dra-I or Cai-I</italic>
###xml 394 401 394 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pfcytb </italic>
Products of the amplification with primers for the identification of wild type pfcytb were restricted with Mph1103-I. Clone K1 and all field samples were cut. None of the field samples amplified with primers for identification of T802A (AAT) and A803C (TCT) mutations was cut with either Dra-I or Cai-I, respectively. According to the enzyme restriction pattern, all samples were identified as pfcytb codon 268 wild type.
###end p 31
###begin title 32
Discussion
###end title 32
###begin p 33
###xml 231 235 231 233 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
In the studied population, no mutations associated to atovaquone-proguanil treatment failure were found. Prevalence of these mutations in Luanda was estimated to be less than 0.77% with a 99% significance level. Therefore, Malarone(R) can be recommended for use by travellers to this region with expected high efficacy. This represents an improvement in view of the known prevalence of resistance against other currently used prophylactic antimalarials.
###end p 33
###begin p 34
###xml 404 406 404 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 407 409 407 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
This was the first work focusing on atovaquone-proguanil treatment failure associated mutations ever done in this area. It gives baseline information of the prevalence of these mutations in the region. After a more extensive atovaquone-proguanil introduction in the market, future studies will be important to monitor these numbers. Screening for the same mutations in Guinea Bissau, Zanzibar and Ghana [29,30] were also negative. Limited use of this antimalarial in endemic countries can explain the low prevalence of resistance-associated mutations. Restricted use by travellers will probably not increase pressure selection of mutants.
###end p 34
###begin p 35
###xml 99 101 99 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
However, other cases of treatment failure, not associated to point mutations, have been described [27]. Study of prevalence of mutations in field samples, especially in treatment failure cases and travellers using the drug for prophylaxis, will help understanding the importance of these mutations in resistance. It is, therefore, imperative to continue surveillance.
###end p 35
###begin title 36
Authors' contributions
###end title 36
###begin p 37
SP carried out the molecular genetic studies, participated in the design of the study and drafted the manuscript.
###end p 37
###begin p 38
FN participated in the conception, design and coordination of the study, helped carrying out the molecular genetic studies, and helped to draft the manuscript.
###end p 38
###begin p 39
###xml 34 42 <span type="species:ncbi:9606">patients</span>
CB was responsible for recruiting patients and collecting blood samples.
###end p 39
###begin p 40
###xml 34 42 <span type="species:ncbi:9606">patients</span>
VQ was responsible for recruiting patients and collecting blood samples.
###end p 40
###begin p 41
JB was responsible for DNA extraction from blood samples.
###end p 41
###begin p 42
LV was responsible for conception, design and coordination of the study, and helped to draft the manuscript.
###end p 42
###begin p 43
VR reviewed critically the manuscript and gave the final approval of the version to be published.
###end p 43
###begin p 44
LB participated in the conception, design and coordination of the study.
###end p 44
###begin p 45
All authors read and approved the final manuscript.
###end p 45
###begin title 46
Acknowledgements
###end title 46
###begin p 47
###xml 28 57 28 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Funda&#231;&#227;o Calouste Gulbenkian </italic>
This study was supported by Fundacao Calouste Gulbenkian (acquisition of primers and disposable materials).
###end p 47
###begin article-title 48
Imported malaria (1985-95): trends and perspectives
###end article-title 48
###begin article-title 49
The use of antimalarial drugs
###end article-title 49
###begin article-title 50
Imported falciparum malaria in Europe: sentinel surveillance data from the European Network on Surveillance of Imported Infectious Diseases
###end article-title 50
###begin article-title 51
Malaria in travelers: a review of the Geosentinel Surveillance Network
###end article-title 51
###begin article-title 52
Malaria Surveillance - United States, 2002
###end article-title 52
###begin article-title 53
###xml 42 64 42 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 42 63 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Assessing the incidence of infection with Plasmodium falciparum among international travelers
###end article-title 53
###begin article-title 54
Surveillance of malaria in European Union countries
###end article-title 54
###begin article-title 55
Imported malaria: prospective analysis of problems in diagnosis and management
###end article-title 55
###begin article-title 56
Site of action of the antimalarial hydroxynaphthoquinone, 2 - [trans - 4 (4' - chlorophenyl) cyclohexyl] - 3 - hydroxy-1, 4-naphthoquinone (566C80)
###end article-title 56
###begin article-title 57
###xml 23 34 23 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium </italic>
Structural features of Plasmodium cytohrome b that may underlie susceptibility to 8-aminoquinolines and hydroxynaphthoquinones
###end article-title 57
###begin article-title 58
Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in malaria parasites
###end article-title 58
###begin article-title 59
Atovaquone - a novel broad-spectrum anti-infective drug
###end article-title 59
###begin article-title 60
A mechanism for the synergistic antimalarial action of atovaquone and proguanil
###end article-title 60
###begin article-title 61
###xml 75 97 75 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 75 96 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Efficacy and safety of atovaquone-proguanil as suppressive prophylaxis for Plasmodium falciparum malaria
###end article-title 61
###begin article-title 62
###xml 43 65 43 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 43 64 <span type="species:ncbi:5833">Plasmodium falciparum</span>
###xml 68 74 <span type="species:ncbi:9606">humans</span>
Prophylatic activity of atovaquone against Plasmodium falciparum in humans
###end article-title 62
###begin article-title 63
###xml 69 74 <span type="species:ncbi:9606">human</span>
Causal prophylactic efficacy of atovaquone-proguanil (Malarone) in a human challenge model
###end article-title 63
###begin article-title 64
###xml 65 87 65 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 65 86 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Atovaquone/Proguanil: A review of its use for the prophylaxis of Plasmodium falciparum malaria
###end article-title 64
###begin article-title 65
###xml 71 93 71 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 71 92 <span type="species:ncbi:5833">Plasmodium falciparum</span>
The safety of atovaquone/proguanil in long-term malaria prophylaxis of Plasmodium falciparum malaria
###end article-title 65
###begin article-title 66
###xml 95 98 95 96 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
Current status and replies to frequently posed questions on atovaquone plus proguanil (Malarone(R)) for the prevention of malaria
###end article-title 66
###begin article-title 67
Malaria chemoprophylaxis: when should we use it and what are the options?
###end article-title 67
###begin article-title 68
###xml 70 92 70 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 70 91 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Malarone treatment failure and in vitro confirmation of resistance of Plasmodium falciparum isolate from Lagos, Nigeria
###end article-title 68
###begin article-title 69
###xml 56 78 56 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 56 77 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Different mutation patterns of atovaquone resistance to Plasmodium falciparum in vitro and in vivo: rapid detection of codon 268 polymorphisms in the cytochrome b as potential in vivo resistance marker
###end article-title 69
###begin article-title 70
###xml 55 77 55 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 55 76 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Genetic confirmation of atovaquone-proguanil resistant Plasmodium falciparum malaria acquired by a non-immune traveller to East Africa
###end article-title 70
###begin article-title 71
###xml 12 34 12 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 12 33 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Evidence of Plasmodium falciparum malaria resistance to atovaquone and proguanil hydrochloride: case reports
###end article-title 71
###begin article-title 72
###xml 120 142 120 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 120 141 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Screening for mutations related to atovaquone-proguanil resistance in treatment failures and other imported isolates of Plasmodium falciparum in Europe
###end article-title 72
###begin article-title 73
Detection of malaria in Malaysia by nested polymerase chain reaction amplification of dried blood spots on filter papers
###end article-title 73
###begin article-title 74
###xml 36 40 36 38 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 75 97 73 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 75 96 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Detection of atovaquone and Malarone(R) resistance conferring mutations in Plasmodium falciparum cytochrome b gene (cytb)
###end article-title 74
###begin article-title 75
###xml 110 132 110 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 110 131 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Prevalence of mutations associated with resistance to atovaquone and to the antifolate effect of proguanil in Plasmodium falciparum isolates from northern Ghana
###end article-title 75

